Propranolol promotes bone formation and limits resorption through novel mechanisms during anabolic parathyroid hormone treatment in female C57BL/6J mice
Authors:
- Annika TreyballATAnnika Treyball
- Audrey C. BergeronABAudrey C. Bergeron
- Daniel J. BrooksDBDaniel J. Brooks
- Audrie L. LanglaisALAudrie L. Langlais
- Hina HashmiHHHina Hashmi
- Kenichi NaganoKNKenichi Nagano
- Deborah BarlowDBDeborah Barlow
- Kathleen T. NevolaKNKathleen T. Nevola
- Karen L. HouseknechtKaren L. Houseknecht
- Roland BaronRBRoland Baron
- Mary L. BouxseinMBMary L. Bouxsein
- Anyonya R. GunturAGAnyonya R. Guntur
Preprint
Abstract
Although the non-selective β-blocker, propranolol, improves bone density with PTH treatment in mice, the mechanism of this effect is unclear. To address this, we used a combination of in vitro and in vivo approaches to address how propranolol influences bone remodeling in the context of PTH treatment. In female C57BL/6J mice, intermittent PTH and propranolol had complementary effects in the trabecular bone of the distal femur and L5 vertebra, with combination treatment achieving micro-architectural parameters beyond that of PTH alone. Combined treatment improved the serum bone formation marker, P1NP, but did not impact other histomorphometric parameters relating to osteoblast function at the L5. In vitro , propranolol amplified the acute, PTH-induced, intracellular calcium signal in osteoblast-like cells. The most striking finding, however, was suppression of PTH-induced bone resorption. Despite this, PTH-induced receptor activator of nuclear factor kappa-B ligand (RANKL) mRNA and protein levels were unaltered by propranolol, which led us to hypothesize that propranolol could act directly on osteoclasts. Using in situ methods, we found Adrb2 expression in osteoclasts in vivo , suggesting β-blockers may directly impact osteoclasts. Taken together, this work suggests a strong anti-osteoclastic effect of non-selective β-blockers in vivo , indicating that combining propranolol with PTH could be beneficial to patients with extremely low bone density.Keywords
All Related Versions
- Published version: Journal of Bone and Mineral Research, 37 (5), 954.
This publication has 49 references indexed in Scilit:
- Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature CommitteeJournal of Bone and Mineral Research, 2012
- Anabolic action of parathyroid hormone regulated by the β 2 -adrenergic receptorProceedings of the National Academy of Sciences, 2012
- Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gainBone, 2012
- Insulin-like growth factor-binding protein-2 is required for osteoclast differentiationJournal of Bone and Mineral Research, 2011
- Low dose of propranolol down‐modulates bone resorption by inhibiting inflammation and osteoclast differentiationBritish Journal of Pharmacology, 2011
- ‘Biasing’ the parathyroid hormone receptor: A novel anabolic approach to increasing bone mass?British Journal of Pharmacology, 2011
- Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrualJournal of Experimental Medicine, 2011
- A Serotonin-Dependent Mechanism Explains the Leptin Regulation of Bone Mass, Appetite, and Energy ExpenditureCell, 2009
- Depression induces bone loss through stimulation of the sympathetic nervous systemProceedings of the National Academy of Sciences, 2006
- Hypoxia suppresses runx2 independent of modeled microgravityJournal of Cellular Physiology, 2004